Literature DB >> 31531445

The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.

Yongjiang Li1, Ciceron Ayala-Orozco2, Pradipta Ranjan Rauta2, Sunil Krishnan3.   

Abstract

Cancer immunotherapy is emerging as a promising treatment modality that suppresses and eliminates tumors by re-activating and maintaining the tumor-immune cycle, and further enhancing the body's anti-tumor immune response. Despite the impressive therapeutic potential of immunotherapy approaches such as immune checkpoint inhibitors and tumor vaccines in pre-clinical and clinical applications, the effective response is limited by insufficient accumulation in tumor tissues and severe side-effects. Recent years have witnessed the rise of nanotechnology as a solution to improve these technical weaknesses due to its inherent biophysical properties and multifunctional modifying potential. In this review, we summarized and discussed the current status of nanoparticle-enhanced cancer immunotherapy strategies, including intensified delivery of tumor vaccines and immune adjuvants, immune checkpoint inhibitor vehicles, targeting capacity to tumor-draining lymph nodes and immune cells, triggered releasing and regulating specific tumor microenvironments, and adoptive cell therapy enhancement effects.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31531445      PMCID: PMC6778734          DOI: 10.1039/c9nr05371a

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  135 in total

1.  Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.

Authors:  Yiran Zheng; Li Tang; Llian Mabardi; Sudha Kumari; Darrell J Irvine
Journal:  ACS Nano       Date:  2017-03-01       Impact factor: 15.881

2.  For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity.

Authors:  Ivan Marquez-Rodas; María Angela Aznar; Antonio Calles; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2018-09-27       Impact factor: 12.531

3.  Cell Penetrating Peptide-Based Redox-Sensitive Vaccine Delivery System for Subcutaneous Vaccination.

Authors:  Kewei Wang; Yong Yang; Wei Xue; Zonghua Liu
Journal:  Mol Pharm       Date:  2018-02-01       Impact factor: 4.939

Review 4.  Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.

Authors:  Barbara Seliger; Chiara Massa; Brian Rini; Jennifer Ko; Jim Finke
Journal:  Trends Mol Med       Date:  2010-03-19       Impact factor: 11.951

5.  Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.

Authors:  Wei Yu; Yitian Wang; Jian Zhu; Libin Jin; Bing Liu; Kaishun Xia; Junjie Wang; Jianqing Gao; Chengzhen Liang; Huimin Tao
Journal:  Biomaterials       Date:  2018-11-13       Impact factor: 12.479

6.  Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.

Authors:  Africa Wallace; Veena Kapoor; Jing Sun; Paul Mrass; Wolfgang Weninger; Daniel F Heitjan; Carl June; Larry R Kaiser; Leona E Ling; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

7.  Stability of Self-Assembled Polymeric Micelles in Serum.

Authors:  Jiao Lu; Shawn C Owen; Molly S Shoichet
Journal:  Macromolecules       Date:  2011-07-08       Impact factor: 5.985

8.  Biopolymer implants enhance the efficacy of adoptive T-cell therapy.

Authors:  Sirkka B Stephan; Alexandria M Taber; Ilona Jileaeva; Ericka P Pegues; Charles L Sentman; Matthias T Stephan
Journal:  Nat Biotechnol       Date:  2014-12-15       Impact factor: 54.908

9.  Co-delivery of Dual Toll-Like Receptor Agonists and Antigen in Poly(Lactic-Co-Glycolic) Acid/Polyethylenimine Cationic Hybrid Nanoparticles Promote Efficient In Vivo Immune Responses.

Authors:  Mahboubeh Ebrahimian; Maryam Hashemi; Mohsen Maleki; Gholamreza Hashemitabar; Khalil Abnous; Mohammad Ramezani; Alireza Haghparast
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

Review 10.  Hypoxia-inducible factors, stem cells, and cancer.

Authors:  Brian Keith; M Celeste Simon
Journal:  Cell       Date:  2007-05-04       Impact factor: 41.582

View more
  8 in total

Review 1.  Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.

Authors:  Xunrui Chen; Wenhui Zhang; Wenyan Yang; Min Zhou; Feng Liu
Journal:  Aging (Albany NY)       Date:  2022-01-17       Impact factor: 5.682

2.  Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy.

Authors:  Linnan Yang; Feng Li; Yongsheng Cao; Qiang Liu; Guoxin Jing; Jintong Niu; Feiyue Sun; Yechang Qian; Shilong Wang; Ang Li
Journal:  J Nanobiotechnology       Date:  2021-10-18       Impact factor: 10.435

Review 3.  Nanotechnology-based products for cancer immunotherapy.

Authors:  Forough Shams; Ali Golchin; Arezo Azari; Leila Mohammadi Amirabad; Fateme Zarein; Atiyeh Khosravi; Abdolreza Ardeshirylajimi
Journal:  Mol Biol Rep       Date:  2021-10-29       Impact factor: 2.742

Review 4.  Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma.

Authors:  Yuanfei Lu; Na Feng; Yongzhong Du; Risheng Yu
Journal:  Nanomaterials (Basel)       Date:  2022-08-17       Impact factor: 5.719

5.  CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.

Authors:  Xiaopei Hao; Yao Zhang; Xiaoli Shi; Hanyuan Liu; Zhiying Zheng; Guoyong Han; Dawei Rong; Chuanyong Zhang; Weiwei Tang; Xuehao Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-09-22

Review 6.  Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy.

Authors:  Blanca Escriche-Navarro; Andrea Escudero; Elena Lucena-Sánchez; Félix Sancenón; Alba García-Fernández; Ramón Martínez-Máñez
Journal:  Adv Sci (Weinh)       Date:  2022-07-22       Impact factor: 17.521

Review 7.  Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?

Authors:  Shiyi Zuo; Jiaxuan Song; Jingxuan Zhang; Zhonggui He; Bingjun Sun; Jin Sun
Journal:  Theranostics       Date:  2021-06-01       Impact factor: 11.556

Review 8.  Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.

Authors:  Elena Gianchecchi; Andrea Arena; Alessandra Fierabracci
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.